Metraipolis › archive › dc_cb177170d46e

HIF1 inhibition targets tumoral and myeloid cells, and is a promising therapy for metastatic castration-resistant prostate cancer — Europe PMC PMID:41896221

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/41896221
DOI
10.1038/s41419-[numero omesso]-8
License (as archived)
solo-consultazione
Archived
2026-11-03T19:52:10.644Z
SHA-256 of the archived text
95f6ddca1af2616aa58c5df66adbd08b246fdc4c1ac9b4852be40cc96c852790
Stable URL of this page
https://metraipolis.com/documento/dc_cb177170d46e

How to cite

HIF1 inhibition targets tumoral and myeloid cells, and is a promising therapy for metastatic castration-resistant prostate cancer — Europe PMC PMID:41896221 — Europe PMC (en), https://europepmc.org/article/MED/41896221 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_cb177170d46e (Metraipolis archive dc_cb177170d46e, sha256 95f6ddca1af2616aa58c5df66adbd08b246fdc4c1ac9b4852be40cc96c852790)
BibTeX
@misc{dccb177170d46e,
  title = {HIF1 inhibition targets tumoral and myeloid cells, and is a promising therapy for metastatic castration-resistant prostate cancer — Europe PMC PMID:41896221},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41896221},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_cb177170d46e; sha256 95f6ddca1af2616aa58c5df66adbd08b246fdc4c1ac9b4852be40cc96c852790},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41896221. Agents can read the archived copy with the MCP tool read_document.